Crossmark

A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England

Crossref DOI link: https://doi.org/10.1186/s13561-025-00640-9

Published Online: 2025-05-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vlachaki, Ioanna

Donhauser, Simon

Madoni, Alessandra

van der Deijl, Marielle

Sharma, Yuvraj

Tzelis, Dimitrios

Guerra, Ines
License Information

Text and Data Mining valid from 2025-05-23

Version of Record valid from 2025-05-23
More Information

Article History

Received: 10 September 2024

Accepted: 14 May 2025

First Online: 23 May 2025

Declarations

:

: The authors declare no competing interests.

: The paper is original, nor all neither any of its parts have been reproduced in other publications.

Document is current

Any future updates will be listed below